Carvedilol Tablet, Film Coated
Product Images NDC 50090-7850

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 50090-7850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Tab Usp Figure1)
A line graph comparing percent mortality over 21 months between placebo and Carvedilol treatment groups. The y-axis shows percent mortality from 0 to 30%, and the x-axis shows time in months from 0 to 21. The graph indicates lower mortality with Carvedilol compared to placebo, with a p-value of 0.0014 noted.*
FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Tab Usp Figure2)
A forest plot depicting hazard ratios with confidence intervals for various subgroups, including men, women, different age groups, racial groups, diabetic status, ischemic status, heart rate categories, systolic blood pressure categories, and spironolactone use. The chart visualizes the risk comparison among these groups with a reference line at a hazard ratio of 1.0.*
FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Tab Usp Figure3)
A line graph depicting mortality percentage over 24 months comparing Carvedilol versus placebo. The x-axis represents time in months and the y-axis shows percentage mortality. Two curves indicate lower mortality for Carvedilol compared to placebo, with a noted significance value of P = 0.03.*
FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Tab Usp Figure4)
A forest plot showing hazard ratios with confidence intervals for various subgroups of patients, including age, gender, timing post-myocardial infarction (MI), prior medication use, clinical characteristics (Killip class, diabetes, hypertension), and heart rate and blood pressure categories. The plot compares outcomes for patients with different clinical features related to cardiac conditions.*
FDA Label Image

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)

Carvedilol Chemical Structure (Carvedilol Tab Usp Structure)
Chemical structure of carvedilol showing its molecular bonds and arrangement, including phenyl, methoxy, and indole groups, depicted as a line diagram with labeled atoms and bonds.*
FDA Label Image

Label Image (Lbl500907850)

Label Image (Lbl500907850)
Label for CARVEDILOL USP 25 mg film-coated tablets by A-S Medication Solutions. Package contains 90 tablets. Instructions note storage below 86 degrees Fahrenheit and protection from moisture. The label includes the product NDC 50090-7850 and a QR code with dosage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.